TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents

International Journal of Antimicrobial Agents

Volumn 30, Issue 4, 2007, Pages 345-351

  Morrissey, I ^a   Colclough, A ^a   Northwood, J ^a  

^a GR Micro Ltd   (United Kingdom)

Author keywords

Fluoroquinolones; QRDR; Respiratory tract infection; Streptococcus pneumoniae; Surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; FRANCE; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIA; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GEOGRAPHY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 34548398406     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.021     Document Type: Article

References (15)

1. Schito G.C., and Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 26 (2006) 479-485
2. Johnson D.M., Stilwell M.G., Fritsche T.R., and Jones R.N. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 5 (2006) 69-74
3. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard. Document M7-A7. Wayne, PA: CLSI; 2006.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Document M100-S16. Wayne, PA: CLSI; 2006.
5. Felmingham D., Reinert R.R., Hirakata Y., and Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 50 Suppl. S1 (2002) 25-37
6. Canton R., Morosini M., Enright M.C., and Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52 (2003) 944-952
7. Deshpande L.M., Sader H.S., Debbia E., Nicoletti G., Fadda G., Jones R.N., and SENTRY Antimicrobial Surveillance Program (2001-2004). Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Diagn Microbiol Infect Dis 54 (2006) 157-164
8. Brown S.D., and Farrell D. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother 54 Suppl. S1 (2004) 23-29
9. Hoban D., Baquero F., Reed V., and Felmingham D. Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000. Int J Infect Dis 9 (2005) 262-273
10. Jones R.N., Biedenbach D.J., and Beach M.L. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 46 (2003) 77-80
11. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 118 (2006) 1287-1292
12. Schurek K.N., Adam H.J., Hoban D.J., and Zhanel G.G. Call for international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. Int J Antimicrob Agents 28 (2006) 266-269
13. Croisier D., Chavanet P., Lequeu C., et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50 (2002) 349-360
14. Fuller J.D., and Low D.E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 41 (2005) 118-121
15. Smith H.J., Noreddin A.M., Siemens C.G., et al. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics. Antimicrob Agents Chemother 49 (2004) 3630-3635